Validation of the Functional Assessment of Cancer Therapy—Lung Symptom Index-12 (FLSI-12)

Eton, David T.; Cella, David; Yount, Susan; Davis, Kimberly M.

doi:10.1016/j.lungcan.2007.03.021

Cited by 18 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To examine potential responders and nonresponders to symptom management, change scores from baseline were calculated for the 12 FLSI time points and classified as improved, worsened or unchanged based on the four-point minimally important difference (80). The proportion of participants in each change group was compared between groups at each week using Mantel-Haenszel Chi-square tests for ordinal data.…”

Section: Resultsmentioning

confidence: 99%

A Randomized Trial of Weekly Symptom Telemonitoring in Advanced Lung Cancer

Yount

Rothrock

Bass

et al. 2014

Journal of Pain and Symptom Management

Self Cite

123

View full text Add to dashboard Cite

Context Lung cancer patients experience multiple, simultaneous symptoms related to their disease and treatment that impair functioning and health-related quality of life (HRQL). Computer technology can reduce barriers to nonsystematic, infrequent symptom assessment and potentially contribute to improved patient care. Objectives To evaluate the efficacy of technology-based symptom monitoring and reporting in reducing symptom burden in patients with advanced lung cancer. Methods This was a prospective, multisite, randomized controlled trial (RCT). Two hundred fifty-three patients were enrolled at three sites and randomized to monitoring and reporting (MR) or monitoring alone (MA). Patients completed questionnaires at baseline, 3, 6, 9 and 12 weeks and symptom surveys via interactive voice response (IVR) weekly for 12 weeks. MR patients’ clinically significant symptom scores generated an e-mail alert to the site nurse for management. The primary endpoint was overall symptom burden; secondary endpoints included HRQL, treatment satisfaction, symptom management barriers, and self-efficacy. Results This RCT failed to demonstrate efficacy of symptom monitoring and reporting in reducing symptom burden compared with monitoring alone in lung cancer. HRQL declined over 12 weeks in both groups (P<0.006 to P<0.025); at week 12, treatment satisfaction was higher in MA than MR patients (P<0.012, P<0.027). Adherence to weekly calls was good (82%) and patient satisfaction was high. Conclusion Feasibility of using a technology-based system for systematic symptom monitoring in advanced lung cancer patients was demonstrated. Future research should focus on identifying patients most likely to benefit and other patient, provider and health system factors likely to contribute to the system’s success.

show abstract

Section: Resultsmentioning

confidence: 99%

A Randomized Trial of Weekly Symptom Telemonitoring in Advanced Lung Cancer

Yount

Rothrock

Bass

et al. 2014

Journal of Pain and Symptom Management

Self Cite

123

View full text Add to dashboard Cite

show abstract

“…The FLSI is an index designed to identify the presence of the major symptoms related to lung cancer, including dyspnea, pain, fatigue, cough, and weight loss 28. These symptoms can negatively influence quality of life.…”

Section: Discussionmentioning

confidence: 99%

Reliability of the Brazilian version of the Functional Assessment of Cancer Therapy-Lung (FACT-L) and the FACT-Lung Symptom Index (FLSI)

Franceschini¹,

Jardim²,

Fernandes³

et al. 2010

Clinics

View full text Add to dashboard Cite

OBJECTIVES:The purpose of this study was to assess the reliability of the Brazilian version of the Functional Assessment of Cancer Therapy‐Lung (FACT‐L) with the FACT‐Lung Symptom Index (FLSI) questionnaire.INTRODUCTION:The assessment of quality of life in patients with lung cancer has become an important evaluative endpoint in current clinical trials. For lung cancer patients, one of the most common quality of life tools available is the FACT‐L. Despite the amount of data available regarding this questionnaire, there are no data on its performance in Brazilian lung cancer patients.METHODS:The FACT‐L with the FLSI questionnaire was prospectively administered to 30 consecutive, stable, lung cancer outpatients at baseline and at 2 weeks.RESULTS:The intraclass correlation coefficient between test and retest for the FACT‐L ranged from 0.79 to 0.96 and for the FLSI was 0.87. There was no correlation between these questionnaire dimensions and clinical or functional parameters.CONCLUSIONS:The Brazilian version of the FACT‐L with FLSI questionnaire is reliable and is quick and simple to apply. This instrument can now be used to properly evaluate the quality of life of Brazilian lung cancer patients.

show abstract

“…19 Finally, the Functional Assessment of Cancer Therapy-Lung (FACT-L) and the Functional Assessment of Chronic Illness Therapy-Spirituality Tool (FACIT-Sp-12) were used to assess multidimensional QoL (physical, social/familial, emotional, functional, spiritual well-being, lung cancer symptom index). 20-24 The FACT-L is 37-item tool with a reported Cronbach's alpha of 0.89. 23 …”

Section: Methodsmentioning

confidence: 99%

Quality of life and symptoms after stereotactic body radiotherapy in early-stage lung cancer patients

Sun¹,

Kim²,

Williams³

et al. 2014

J Community Support Oncol

View full text Add to dashboard Cite

Background Stereotactic body radiotherapy (SBRT) has emerged in recent years as a clinically viable treatment option for early-stage non-small-cell lung cancer (NSCLC) patients. Comprehensive assessment of quality of life (QoL) after SBRT is relatively sparse. Objective To describe QoL and symptoms in a small, prospective cohort of early-stage NSCLC patients treated with SBRT. Methods 19 NSCLC patients who were medically unfit for surgery or chose not to undergo surgery were included in the study. All of the patients were treated with SBRT between 2009 and 2013 at a single comprehensive cancer center. Patients completed a baseline assessment of functional and cognitive status, symptoms, psychological distress, and overall QoL. Questionnaires were repeated at 6 and 12 weeks after accrual. Results There were no significant differences in all outcomes across the 3 evaluation time points. Overall QoL scores were moderate, and the lowest score was observed for the functional well-being domain. The most severe symptoms at baseline were pain, lack of energy, cough, nervousness, difficulty sleeping, shortness of breath, and worry. Severity scores for pain, lack of energy, and cough increased, whereas nervousness, difficulty sleeping, and worry decreased at the 12 week evaluation. Limitations Small sample size and lack of sufficient diversity in the cohort. Conclusions QoL scores remained relatively stable across time. Anxiety improved after SBRT, whereas symptoms such as generalized pain, lack of energy, and cough worsened. The findings suggest that SBRT is overall a well-tolerated treatment with no significant decrement in patient-centered outcomes.

show abstract

Validation of the Functional Assessment of Cancer Therapy—Lung Symptom Index-12 (FLSI-12)

Cited by 18 publications

References 24 publications

A Randomized Trial of Weekly Symptom Telemonitoring in Advanced Lung Cancer

A Randomized Trial of Weekly Symptom Telemonitoring in Advanced Lung Cancer

Reliability of the Brazilian version of the Functional Assessment of Cancer Therapy-Lung (FACT-L) and the FACT-Lung Symptom Index (FLSI)

Quality of life and symptoms after stereotactic body radiotherapy in early-stage lung cancer patients

Contact Info

Product

Resources

About